Drug
nivolumab and relatlimab-rmbw
Marketed as OPDUALAG.
Generic name
nivolumab and relatlimab-rmbw
Brand names
OPDUALAG
First FDA approval
2022-03-18
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA761234 | OPDUALAG | 2022-03-18 | BRISTOL MYERS SQUIBB |
Manufacturers
BRISTOL MYERS SQUIBB
Frequently asked questions
When was nivolumab and relatlimab-rmbw FDA approved?
Earliest FDA approval on record: 2022-03-18.
What brand names are sold as nivolumab and relatlimab-rmbw?
OPDUALAG.
Sources
Appeal a nivolumab and relatlimab-rmbw denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com